Losartan Potassium
Product Images NDC 53002-4643

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 53002-4643). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rpk Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl530024643)

Losartan Potassium 50 mg tablets packaging label from RPK Pharmaceuticals, Inc. The label indicates the product is a generic for Cozaar, with 100 white oval tablets per container. It includes dosing instructions to take one tablet daily or as directed, and various required prescription label fields. The NDC is 53002-4643-01.*

FDA Label Image

Losartanaddress2 (Losartanaddress2)

FDA Label Image

Losartanfigure1 (Losartanfigure1)

A line graph comparing the percentage of patients with a primary endpoint over study months between Atenolol (dotted line) and Losartan potassium (solid line) treatments. The x-axis represents study months from 0 to 60, and the y-axis shows the percentage of patients up to 16%. The graph includes an adjusted risk reduction of 13% with a p-value of 0.021.*

FDA Label Image

Losartanfigure2 (Losartanfigure2)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over 66 months of study, showing two lines for Atenolol and Losartan Potassium. The graph indicates a lower stroke incidence with Losartan Potassium, with an adjusted risk reduction of 25% and p=0.001.*

FDA Label Image

Losartanfigure3 (Losartanfigure3)

Figure 3 is a forest plot showing primary endpoint events within demographic subgroups for Losartan Potassium versus Atenolol. It compares event rates and hazard ratios for primary composite events and fatal/non-fatal stroke across categories such as age, gender, race, isolated systolic hypertension, diabetes, and history of cardiovascular disease.*

FDA Label Image

Losartanfigure4 (Losartanfigure4)

A line graph showing the percentage of patients with an event over 48 months, comparing Losartan potassium to placebo. The graph highlights a risk reduction of 16.1% with Losartan potassium and includes a p-value of 0.022, indicating statistical significance.*

FDA Label Image

Losartanstructure (Losartanstructure)

Chemical structure of Losartan Potassium showing its characteristic molecular components, including a potassium ion (K+), chlorine (Cl), and distinct ring systems such as a biphenyl and tetrazole group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.